Clinical Trial Results Show Rilzabrutinib as Effective Pemphigus Treatment
stevepb / Pixabay

Clinical Trial Results Show Rilzabrutinib as Effective Pemphigus Treatment

  Last month, at the American Academy of Dermatology (AAD) Virtual Annual Meeting, Dr. Dedee F. Murrell, MD, explained the efficacy of rilzabrutinib for treating pemphigus. According to MDedge, many…

Continue Reading Clinical Trial Results Show Rilzabrutinib as Effective Pemphigus Treatment
Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
source: pixabay.com

Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis

  According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…

Continue Reading Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
Study Confirms the Superiority of Rituximab (Rituxan) in Treating Pemphigus Vulgaris
stevepb / Pixabay

Study Confirms the Superiority of Rituximab (Rituxan) in Treating Pemphigus Vulgaris

According to a story from marketscreener.com, the biotechnology company Roche recently announced the results from a company sponsored phase 3 clinical trial that compared the safety and efficacy of rituximab…

Continue Reading Study Confirms the Superiority of Rituximab (Rituxan) in Treating Pemphigus Vulgaris

Positive Results from Phase 2 Trial Could Lead to Lower Doses of Corticosteroids for Pemphigus Patients

Pemphigus Pemphigus is a rare autoimmune condition which causes the skin to blister. There are two main forms of the disease called pemphigus foliaceus (PF) and pemphigus vulgaris (PV). Pemphigus…

Continue Reading Positive Results from Phase 2 Trial Could Lead to Lower Doses of Corticosteroids for Pemphigus Patients
First Major Treatment Advance for PV Has Been Approved by the FDA
Source: pixabay.com

First Major Treatment Advance for PV Has Been Approved by the FDA

  According to BioSpace, a new treatment for pemphigus vulgaris (PV) has been recently approved by the U.S. Food and Drug Administration. The treatment, Rituxan (rituximab), is geared towards adults who have…

Continue Reading First Major Treatment Advance for PV Has Been Approved by the FDA

Editor’s Choice: Powerful Purple Crayons and Supermoms

Welcome to Friday Patient Worthians! This week we have stories on cystinosis and super moms with sickle cell! Additionally, we have a patient story on dystonia and an upcoming event. Lastly, an…

Continue Reading Editor’s Choice: Powerful Purple Crayons and Supermoms
Dental Student Awareness: Boston University
Source: The International Pemphigus and Pemphigoid Foundation

Dental Student Awareness: Boston University

The below article was originally published on May 31st, 2017 on the International Pemphigus and Pemphigoid Foundation website, and is being republished here with permission. It wasn’t easy getting to…

Continue Reading Dental Student Awareness: Boston University

Editor’s Choice: Consequences of Unintentional Exploitation in Rare Disease

Happy Spring Patient Worthians! This week we have pieces from two rare women, one battling the rare disease pemphigus vulgaris, part of the pemphigus and pemphigoid family. The other is…

Continue Reading Editor’s Choice: Consequences of Unintentional Exploitation in Rare Disease
Close Menu